



## Benjamin Fuhrmann

### Associate

T 416.367.7864  
F 416.367.6749  
Toronto  
[BFuhrmann@blg.com](mailto:BFuhrmann@blg.com)  
[LinkedIn](#)

[Corporate Commercial](#)  
[Corporate Governance](#)  
[Health Care & Life Sciences](#)  
[Health Regulatory](#)  
[MedTech](#)  
[Charities & Not-For-Profit](#)  
[Products Law](#)  
[Technology](#)

Ben practices corporate and commercial law with a focus on the health and life sciences sectors.

Ben maintains a corporate and commercial practice that includes advising on a broad range of matters including mergers and acquisitions, corporate governance, and commercial agreements. He has particular experience in the charities and not-for-profit spaces. Ben is uniquely positioned to advise companies on potential litigation risk given his previous experience as a litigator at BLG.

Much of Ben's regulatory and life sciences practice involves advising clients in the medical device, pharmaceutical, and consumer product industries as to compliance with applicable regulatory frameworks, including those pertaining to advertising and recalls. Ben also assists hospitals, clinics, and individual healthcare practitioners comply with a wide range of federal and provincial health-related regulations and policies. Ben has helped clients respond to investigations and complaints by regulators like Health Canada and the College of Physicians and Surgeons of Ontario.

Prior to attending law school, Ben completed a Master of Science degree in Immunology. His research focused on developing new immunosuppression medication for kidney transplant patients.

## Insights & Events

- Author, "Health Canada's evolving regulatory framework for machine learning-enabled medical devices", BLG Article, February 2025
- Author, "Better guidance equals better reporting: Navigating the Supply Chains Act for year 2 reporting", BLG Article, November 2024
- Author, "Introduction to the Pharmacare Act: A New Era for Pharmacare in Canada", BLG Article, October 2024
- Author, "Modern slavery reporting: Key lessons from Public Safety Canada's 2024 annual report to Parliament", BLG Article, October 2024
- Author, "Regulatory framework of laboratory developed tests: Canada vs U.S.", BLG Article, July 2024
- Co-Author, "Q&A: defamation claims in Canada," Lexology, October 2023.
- Author, "Health Canada releases draft pre-market guidance for machine learning medical devices", BLG Article, September 2023
- Author, "The Canadian legal landscape on AI enabled medical devices", BLG Article, June 2023
- Author, "Hansman v. Neufeld – SCC decision confirms that certain “counter-speech” is deserving of protection", BLG Article, May 2023
- Author, "Health Canada releases guiding principles on artificial intelligence and machine learning for medical devices", BLG Article, November 2021
- Author, "Health Canada regulatory spotlight on medical device post-market surveillance", BLG Article, November 2021
- Author, "ON court: Class actions appropriate procedure for negligent misrepresentation claim", BLG Article, July 2020

## Beyond Our Walls

### Professional involvement

- Member, Law Society of Ontario
- Member, Ontario Bar Association

## Bar Admission & Education

- Ontario, 2022
- JD, Western University, 2021
- MSc. Immunology, Western University, 2018
- B.Sc. (Hons.) Microbiology & Immunology, Western University, 2016



---

## **BLG | Canada's Law Firm**

As the largest, truly full-service Canadian law firm, Borden Ladner Gervais LLP (BLG) delivers practical legal advice for domestic and international clients across more practices and industries than any Canadian firm. With over 725 lawyers, intellectual property agents and other professionals, BLG serves the legal needs of businesses and institutions across Canada and beyond – from M&A and capital markets, to disputes, financing, and trademark & patent registration.

[\*\*blg.com\*\*](https://www.blg.com)

© 2025 Borden Ladner Gervais LLP. Borden Ladner Gervais LLP is an Ontario Limited Liability Partnership.